Ezh2 represses effector genes that contribute to the development of tumor-mediated CD8+ T-cell exhaustion
5 affiliations
- 1Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- 21University of Pittsburgh, Pittsburgh, USA
- 3University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
- 4Department of Pediatrics, Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- 5Center for Systems Immunology, Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
Abstract
Background CD8+ T cells differentiate into terminally exhausted T cells, a hypofunctional state induced in tumor environments that leads to impaired antitumor immunity and poor cancer prognosis. Therapeutic approaches to improve effector CD8+ T-cell function by limiting or reversing tumor-mediated exhaustion are areas of active investigation. Terminally exhausted CD8+ T cells from tumors exhibit increased transcriptional repression of effector genes by tri-methylation of histone 3 lysine 27 (H3K27me3). Enhancer of zeste homolog 2 (Ezh2) is a crucial enzyme acting as the catalytic core of the polycomb repressive complex 2, which adds H3K27me3 in T cells.Methods Using pharmacologic and genetic suppression of Ezh2, we evaluated its role in driving CD8+ T-cell exhaustion in vitro and in murine melanoma models in vivo, including its impact on functional restoration.Results Ezh2 expression is significantly increased in CD8+ T cells exposed to chronic stimulation. Suppression of Ezh2 significantly increased the proportion of CD8+ T cells expressing both tumor necrosis factor and interferon-γ when exposed to chronic stimulation in vitro or in the tumor. Ezh2-deficient CD8+ T cells also exhibited decreases in the exhaustion-mediated transcription factor Tox. Multiple genes were upregulated when Ezh2 was deleted, including cytokines related to type 1 (eg, Gzmc) and type 2 (eg, Il13) immunity, and treatment with interleukin (IL)-4 induced a significantly higher proportion of IL-13-expressing CD8+ T cells.Conclusions These findings suggest that Ezh2 contributes to epigenetic modifications supporting T-cell exhaustion, and Ezh2 suppression or deletion can rescue effector functions of exhausted CD8+ T cells. Thus, Ezh2 may be a therapeutic target to improve antitumor immunity.
Related
- 772 TOX maintains T cell exhaustion and hinders the development of tumor-specific CD8+ T cell memory
- Interaction with complement factor C1q can contribute to and improve monoclonal antibody-mediated protection against lethal HSV-1 challenge
- Angiopoietin-like protein 7 (ANGPTL7)-mediated effects on resident immune cells contribute to neurodegeneration in glaucomatous optic nerve head
- A self-limiting dimeric TIR effector specialised for type III CRISPR-mediated immunity
- Sph-mediated mtDNA release and autophagy-dependent ferroptosis contribute to Staphylococcus aureus-induced mastitis
BibTeX
@article{delgoffe2026ezh2,
title = {{Ezh2 represses effector genes that contribute to the development of tumor-mediated CD8+ T-cell exhaustion}},
author = {Greg M Delgoffe and Hannah Bumgarner and Catherine Yang and Aaron Yang and Amanda C Poholek and Xingjian Qiu and B Rhodes Ford and Shilpi Giri},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
month = nov,
doi = {10.1136/jitc-2026-016004},
url = {https://doi.org/10.1136/jitc-2026-016004},
note = {CC BY},
}
RIS
TY - JOUR
TI - Ezh2 represses effector genes that contribute to the development of tumor-mediated CD8+ T-cell exhaustion
AU - Greg M Delgoffe
AU - Hannah Bumgarner
AU - Catherine Yang
AU - Aaron Yang
AU - Amanda C Poholek
AU - Xingjian Qiu
AU - B Rhodes Ford
AU - Shilpi Giri
PY - 2026
DA - 2026/11/16
JO - Journal for ImmunoTherapy of Cancer
DO - 10.1136/jitc-2026-016004
UR - https://doi.org/10.1136/jitc-2026-016004
AB - Background CD8+ T cells differentiate into terminally exhausted T cells, a hypofunctional state induced in tumor environments that leads to impaired antitumor immunity and poor cancer prognosis. Therapeutic approaches to improve effector CD8+ T-cell function by limiting or reversing tumor-mediated exhaustion are areas of active investigation. Terminally exhausted CD8+ T cells from tumors exhibit increased transcriptional repression of effector genes by tri-methylation of histone 3 lysine 27 (H3K27me3). Enhancer of zeste homolog 2 (Ezh2) is a crucial enzyme acting as the catalytic core of the polycomb repressive complex 2, which adds H3K27me3 in T cells.Methods Using pharmacologic and genetic suppression of Ezh2, we evaluated its role in driving CD8+ T-cell exhaustion in vitro and in murine melanoma models in vivo, including its impact on functional restoration.Results Ezh2 expression is significantly increased in CD8+ T cells exposed to chronic stimulation. Suppression of Ezh2 significantly increased the proportion of CD8+ T cells expressing both tumor necrosis factor and interferon-γ when exposed to chronic stimulation in vitro or in the tumor. Ezh2-deficient CD8+ T cells also exhibited decreases in the exhaustion-mediated transcription factor Tox. Multiple genes were upregulated when Ezh2 was deleted, including cytokines related to type 1 (eg, Gzmc) and type 2 (eg, Il13) immunity, and treatment with interleukin (IL)-4 induced a significantly higher proportion of IL-13-expressing CD8+ T cells.Conclusions These findings suggest that Ezh2 contributes to epigenetic modifications supporting T-cell exhaustion, and Ezh2 suppression or deletion can rescue effector functions of exhausted CD8+ T cells. Thus, Ezh2 may be a therapeutic target to improve antitumor immunity.
SN - 2051-1426
ER -